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Background: Sepsis is a systemic inflammatory response syndrome caused by infectious disease. Severe sepsis and
septic shock are extremely serious conditions with poor prognoses. It is reported that cytokines are deeply involved
in the disease mechanism. Continuous hemodiafiltration (CHDF) using a poly(methyl methacrylate) (PMMA)
membrane is reported to adsorb various cytokines and improve the status of patients with sepsis. Recently, another
cytokine-adsorbing hemofilter, acrylonitrile-co-methallyl sulfonate surface-treated (AN69ST) membrane, has become
available for CHDF in patients with sepsis. However, the clinical efficacy of this membrane remains unclear.
Therefore, in this study, we compared the efficacy of AN69ST and PMMA membranes.
Methods: This retrospective study included patients with severe sepsis or septic shock who underwent CHDF for at
least 24 h in the intensive care unit from January 2013 to August 2016.
Results: This study included 49 patients who underwent CHDF, 32 using an AN69ST membrane and 17 using a
PMMA membrane. In the AN69ST and PMMA groups, average age was 71.1 ± 11.4 years and 74.7 ± 9.4 years,
respectively, and percentage of men was 71.9 and 88.2%, respectively. Severity of sepsis and vital signs were not
significantly different between groups at the start of CHDF. In addition, 28-day mortality was not significantly
different between groups (43.8 vs. 35.3%, P = 0.1625). However, heart rate in the AN69ST group decreased
significantly early in the course of CHDF (6, 12, and 24 h, P < 0.05) compared with the PMMA group.
Conclusions: AN69ST and PMMA membranes showed equivalent efficacy. Furthermore, CHDF using an AN69ST
membrane may be effective for early stabilization of vital signs.
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Sepsis is a systemic inflammatory response syndrome
caused by infectious disease [1]. Severe sepsis and sep-
tic shock are extremely serious conditions with poor
prognoses [2, 3]. It is reported that cytokines are deeply
involved in the disease mechanism. Although various
treatments for sepsis have been used, none has been
sufficient. Of the available options, blood purification
therapy for cytokine removal is reported to be success-
ful [4]. With regard to high-flow and high-volume renal* Correspondence: zhangren_at_23@yahoo.co.jp
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negative [7, 8], with no clear conclusion. However, con-
tinuous renal replacement therapy (CRRT), which
removes cytokines by taking advantage of the character-
istics of membranes, such as poly(methyl methacrylate)
(PMMA), is often used [9, 10]. Although another
hemofilter, acrylonitrile-co-methallyl sulfonate surface-
treated (AN69ST) membrane, has recently become
available in Japan [11], results regarding its clinical effi-
cacy are scarce. In addition, there is no study compar-
ing the AN69ST membrane with another hemofilter
with cytokine-adsorption ability, such as PMMA.
Therefore, in this study, we investigated the clinical
efficacy of the AN69ST membrane in the acute phase.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Baseline characteristics of patients treated with CHDF
Parameter AN69ST (n = 32) PMMA (n = 17) P value
Male (%) 71.9 88.2 0.1914
Age (years) 71.1 ± 11.4 74.7 ± 9.4 0.1123
Height (cm) 159.8 ± 8.9 160.7 ± 9.2 0.7845
BMI 22.4 ± 4.7 21.6 ± 3.8 0.4371
Cause of sepsis
Peritonitis (%) 46.9 64.7 0.2339
UTI (%) 6.3 11.8 0.5022
Pneumoniae (%) 15.6 11.8 0.7132
Infection bacteria
Gram-positive coccus (%) 40.6 41.2 0.9702
Gram-negative rod (%) 34.4 47.1 0.3857
Unknown (%) 31.3 23.5 0.5691
Past history
Diabetes (%) 21.9 23.5 0.8949
Hypertension (%) 53.1 35.3 0.2339
Maintenance dialysis (%) 12.5 29.4 0.1456
Ventilator (%) 84.4 94.1 0.3220
Surgical treatment (%) 50.0 76.5 0.0727
SBP (mmHg) 105.2 ± 26.8 107.9 ± 21.7 0.4945
DBP (mmHg) 54.3 ± 13.2 57.6 ± 15.7 0.5012
MBP (mmHg) 71.3 ± 15.9 74.3 ± 16.6 0.5777
HR (bpm) 99.1 ± 22.0 99.8 ± 17.2 0.9828
BT (°C) 37.3 ± 1.0 36.9 ± 1.1 0.0740
CAI 38.5 ± 27.3 28.4 ± 19.2 0.1689
DOA (μg/kg/min) 0.00 ± 0.00 0.55 ± 2.28 0.1573
DOB (μg/kg/min) 0.89 ± 2.00 0.55 ± 2.28 0.1918
NA (μg/kg/min) 0.38 ± 0.26 0.27 ± 0.19 0.1472
WBC (1000/μL) 15.4 ± 9.5 11.8 ± 11.0 0.1035
Hb (g/dL) 10.6 ± 2.1 10.3 ± 1.4 0.4749
Plt (10,000/μL) 14.5 ± 10.8 13.6 ± 7.4 0.8091
ALB (g/dL) 2.0 ± 0.5 1.9 ± 0.5 0.6591
AST (IU/L) 310.1 ± 754.4 285.7 ± 999.8 0.2610
ALT (IU/L) 172.2 ± 440.3 118.2 ± 388.2 0.1753
UN (mg/dL) 57.2 ± 24.3 48.0 ± 26.1 0.1252
Cr (mg/dL) 3.6 ± 2.2 3.9 ± 3.6 0.4067
eGFR (ml/min/1.7 m2) 19.0 ± 12.9 25.8 ± 19.0 0.4127
Na (mEq/L) 138.2 ± 4.1 137.8 ± 6.3 0.2291
K (mEq/L) 4.5 ± 1.0 4.3 ± 0.8 0.3714
cCa (mg/dL) 9.4 ± 0.9 9.4 ± 0.9 0.8058
P (mg/dL) 4.6 ± 1.7 4.7 ± 1.9 0.8148
Mg (mg/dL) 2.0 ± 0.5 1.8 ± 0.3 0.3516
CRP (mg/dL) 20.4 ± 12.5 14.8 ± 12.2 0.0991
HCO3
− (mEq/L) 16.9 ± 5.6 17.0 ± 4.3 0.8500
Lactate (mg/dL) 40.4 ± 32.3 23.9 ± 15.3 0.0928
Table 1 Baseline characteristics of patients treated with CHDF
(Continued)
APACHE 2 32.1 ± 7.0 32.5 ± 4.8 0.8086
APACHE2 without kidney 29.3 ± 7.1 30.2 ± 4.9 0.7120
SOFA 13.1 ± 2.7 11.9 ± 2.7 0.0807
SOFA without kidney 10.4 ± 2.3 9.5 ± 2.8 0.4709
PMX (%) 25.0 58.8 0.0194*
CRRT (days) 4.4 ± 2.9 5.3 ± 4.9 0.8970
Death at 28 days (%) 43.8 35.3 0.1625
Cr at 28 days (mg/dL) 1.4 ± 1.3 (n = 14) 2.5 ± 1.9 (n = 9) 0.0777
CHDF continuous hemodiafiltration, AN polyacrylonitrile, PMMA polymethyl
methacrylate, BMI body-mass index, UTI urinary tract infection, SBP systolic
blood pressure, DBP diastolic blood pressure, MBP mean blood pressure,
HR heart rate, BT body temperature, CAI catecholamine index, DOA dopamine,
DOB dobutamine, NA noradrenalin, WBC white blood cells, Hb hemoglobin,
Plt platelet, ALB albumin, AST aspartate aminotransferase, ALT alanine amino-
transferase, eGFR estimated glomerular filtration rate, Na sodium, K potassium,
cCa corrected calcium, P phosphate, Mg magnesium, CRP C-reactive protein,
HCO3
− bicarbonate, APACHE 2 Acute Physiology and Chronic Health Evaluation
II score, SOFA sequential organ failure assessment score, PMX polymyxin
B-immobilized fiber column hemoperfusion, CRRT continuous renal
replacement therapy
*p < 0.05
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Patients and data collection
This retrospective study included patients with severe
sepsis or septic shock who underwent CRRT for at least
24 h in the intensive care unit from January 2013 to
August 2016. Sepsis was diagnosed by meeting at least
two systemic inflammatory response syndrome criteria
due to a presumed infection [1]. Severe sepsis is that
causing organ dysfunction. As CRRT, continuous hemo-
diafiltration (CHDF) was performed, starting with a
dialysate flow rate of 400 mL/h and a replacement solu-
tion flow rate of 400 mL/h, which was adjusted appro-
priately. A double-lumen catheter was placed in the
internal jugular vein as vascular access. Heparin and/or
nafamostat mesylate was used with judgment in each
case. Judgment of when to start and finish CHDF was
determined by consultation with multiple intensive care
staff members and nephrologists. The membranes used
for CHDF were PMMA and AN69ST.
At the start of CHDF, patients’ age, sex, physical find-
ings, cause of sepsis, and laboratory data were collected
from their medical records. Acute Physiology and
Chronic Health Evaluation II (APACHE II) [12] and se-
quential organ failure assessment (SOFA) [13] scores
also were calculated. Vital signs and catecholamine
index (CAI) were evaluated at the start of CHDF and at
6, 12, 24, 48, and 72 h. Twenty-eight-day survival rate
was also calculated. Patients’ vital signs and CAI at 72 h
were included even if CHDF was already finished at that
time. CAI was calculated as follows: dopamine level (μg/
kg/min) + dobutamine level (μg/kg/min) + noradrenaline
level (μg/kg/min) × 100.
Fig. 2 Survival rates among subgroups stratified according to Acute
Physiology and Chronic Health Evaluation II (APACHE II) score
without kidney score. AN69ST acrylonitrile-co-methallyl sulfonate
surface-treated, NS not significant, PMMA poly(methyl methacrylate)
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Baseline characteristics were presented descriptively with
average and SD values and were tested using the Mann-
Whitney U test for parametrical data and χ2 test for
nonparametrical data. Logistic regression analysis and
stratified analysis were performed to evaluate 28-day




Table 1 shows the clinical characteristics of the 49
patients included in this study. Of them, 32 underwent
CHDF using an AN69ST membrane, while 17 used a
PMMA membrane; average age was 71.1 ± 11.4 years
and 74.7 ± 9.4 years, respectively, and percentage of men
was 71.9 and 88.2%, respectively. As a result, almost all
CHDF was performed with AN69ST membrane after be-
coming available although discussed by multiple inten-
sive care staff members and nephrologists. Severity of
sepsis and vital signs at the start of CHDF were not sig-
nificantly different between groups. The percentage of
ventilator user did not show significant difference be-
tween both groups. Compared with patients using an
AN69ST membrane, those using a PMMA membrane
received combination therapy with polymyxin B-
immobilized fiber column hemoperfusion (PMX) more
frequently (58.8 vs. 25.0%, P = 0.0194).
Comparison of 28-day mortality
Figure 1 shows the Kaplan-Meier plot of 28-day sur-
vival in patients who underwent CHDF using an
AN69ST or PMMA membrane. Twenty-eight-day mor-
tality was not significantly different between groups
(43.8 vs. 35.3%, P = 0.1625). Figures 2 and 3 showFig. 1 Kaplan-Meier plot of 28-day survival in patients who underwent
continuous hemodiafiltration using a poly(methyl methacrylate)
(PMMA) or acrylonitrile-co-methallyl sulfonate surface-treated
(AN69ST) membranestratified analysis according to APACHE II and SOFA
scores without kidney score. Figure 4 shows the forest
plot of odds ratios for 28-day survival. Stratified and
multivariate analyses showed no significant difference
in mortality between groups. Furthermore, the level of
creatinine at 28 days was not different significantly
(Table 1).
Time course of vital signs and CAI
Figure 5a shows blood pressure in patients who under-
went CHDF using an AN69ST or PMMA membrane.Fig. 3 Survival rates among subgroups stratified according to
Sequential Organ Failure Assessment (SOFA) score without kidney
score. AN69ST acrylonitrile-co-methallyl sulfonate surface-treated,
NS not significant, PMMA poly(methyl methacrylate)
Fig. 4 Forest plot of odds ratios (ORs) for 28-day survival with continuous hemodiafiltration using an acrylonitrile-co-methallyl sulfonate
surface-treated (AN69ST) membrane. APACHE II Acute Physiology and Chronic Health Evaluation II, CI confidence interval, MBP mean blood
pressure, PMX polymyxin B-immobilized fiber column hemoperfusion
Fig. 5 a, b Time course of vital signs. *P < 0.05; **P < 0.01. AN69ST acrylonitrile-co-methallyl sulfonate surface-treated, BT body temperature, DBP
diastolic blood pressure, HR heart rate, MBP mean blood pressure, NS not significant, PMMA poly(methyl methacrylate), SBP systolic blood pressure
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Figure 5b shows heart rate (HR) and body temperature
in such patients. Early in the course of CHDF (6, 12, and
24 h), patients using an AN69ST membrane showed
more stable HR than those using a PMMA membrane.
Figure 6 shows various parameters which affect vital
signs. There was no difference in CAI, fluid removal
rate, or the level of albumin.
Discussion
In this study, we compared patients with sepsis who
underwent CHDF using an AN69ST or PMMA mem-
brane. AN69ST and PMMA membranes showed equiva-
lent survival. Furthermore, patients using an AN69ST
membrane demonstrated rapid stabilization of HR.
There has been no report comparing the clinical effi-
cacy of AN69ST and PMMA membranes. Our study is
distinctive in that we focused on patients with sepsis.
Some previous studies have reported that CHDF using
an AN69ST membrane showed significantly better sur-
vival than expected in patients with sepsis [14, 15]. The
present report showed nearly equal survival between
AN69ST and PMMA membranes, indicating the effect-
iveness of AN69ST. However, the expected survival rate
from APACHE II scores is of a considerably old age, and
caution is necessary because survival is considered to be
further improved by the current progress in treatment.
When performing CHDF, there are renal and nonrenal
indications. In the latter case, cytokine removal is the
main purpose. In patients with sepsis, cytokine storm
plays a central role in the pathologic condition, and
cytokine removal is considered to be effective, as in this
study. In the present study, there were no significant dif-
ferences in urea nitrogen or creatinine levels at the start
of CHDF between groups. Furthermore, because mul-
tiple intensive care unit physicians and nephrologists atFig. 6 Time course of various parameters. ALB albumin, AN69ST acrylonitrile
NS not significant, PMMA poly(methyl methacrylate)a single institution decided when to start and finish
CHDF by discussion, there was little deviation in the cri-
teria for CHDF, even though different membranes with
cytokine-adsorption ability were selected. In this study,
although we did not measure the levels of cytokines, we
presumed that rapid HR stabilization was due to cyto-
kine removal because other parameters which affect HR,
such as body temperature, dose of dopamine, fluid
removal rate, and the level of albumin, did not show sig-
nificant difference between both groups.
In our study, although the differences were not signifi-
cant, the AN69ST group tended to have more severe
values for SOFA score, lactate level, and CAI. However,
the equivalent survival between groups seems to indicate
the effectiveness of the AN69ST membrane. In addition,
HR stabilized faster in the AN69ST group than in the
PMMA group. We consider that this may be due to the
difference in mechanisms: the AN69ST membrane ad-
sorbs cytokines by utilizing an electrical charge, while
the PMMA membrane adsorbs cytokines by ensnaring
them in the surface pores [16]. However, because we did
not measure cytokine level, we are not able to discuss
this point further. Nonetheless, it is possible that cyto-
kine easily removed by the AN69ST membrane contrib-
uted to earlier improvement of vital signs.
For comparison between membranes, we targeted
patients who underwent CHDF for more than 24 h.
Patients who died within 24 h after the start of CHDF
were too critical to evaluate the differences between
membranes. These most severe cases have pathologic
conditions with advanced organ dysfunction and may
require intensive treatment at an earlier stage.
The prevalence of PMX usage was significantly higher
in PMMA group. In this study, after becoming available,
almost all CHDF was performed using AN69ST mem-
brane without PMX. It may be a facility trend. Because-co-methallyl sulfonate surface-treated, CAI catecholamine index,
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in AN69ST membrane group with low prevalence of
PMX usage may be showing advantageous aspect, com-
paring to PMMA group with higher prevalence of PMX
usage.
On the other hand, cost of medical equipments is an
important problem. As of 2016 in Japan, AN69ST mem-
brane is about 10% more expensive than PMMA mem-
brane. In this study, we did not examine the life span of
membranes because we changed membranes every 24 h
before clotting. If life span of AN69ST membrane is lon-
ger, the cost problem may be solved.
Our study has some limitations. First, because this was
a retrospective study, the backgrounds of both groups
were not completely matched. In addition, criteria for
the start of CHDF were not clearly defined. However,
because multiple physicians determined when to start
and finish CHDF by discussion, it is considered that
there was no large deviation in judgment. Nonetheless,
the start and end criteria for CHDF should be clear.
Second, we did not measure the cytokine level. Because
HR was stabilized early in the AN69ST group, we should
determine whether this was due to the type of cytokines
that can be removed.
Conclusions
Patients who underwent CHDF using an AN69ST or
PMMA membrane showed similar prognoses. Further-
more, CHDF using an AN69ST membrane may be ef-
fective for early stabilization of vital signs.
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